Q3 2025 Management View CEO Leonard Schleifer reported "double-digit net sales growth for 3 of our leading products," ...

Regeneron’s third quarter results were well received by the market, reflecting strong execution in its commercial portfolio and key products. Management attributed the positive momentum to ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...

Sanofi posted strong Q3 results amid currency challenges; discover key pipeline updates and growth prospects for investors.

Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results , but sales were flat year on year at $3.75 billion. Its ...

Sanofi and Regeneron’s immunology blockbuster Dupixent had been on a mini streak as king of the pharma airwaves but was knocked off its perch in June by AbbVie’s competing drug Rinvoq. That’s ...

Over the years, as Sanofi and Regeneron's Dupixent racked up new indications and approached the French pharma giant's 10 billion euro peak sales goal, analysts had started to wonder whether the drug ...

Dupixent started 2023 the way it ended 2022: at the top. The severe asthma treatment had the largest impressions share of voice (SOV) among Rx and over-the-counter pharma brands in January, totaling ...

Dupixent had the most impressions and largest impressions share of voice (SOV) among Rx and over-the-counter (OTC) brands in March, according to data released by iSpot.tv Monday evening. This is a ...

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic ...